Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahi Ahmadi, Manish Gupta, Steven Xu

Blood (2023) 142 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2023-181322

Published: 2023

Journal Articles

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, Matthew Putnins, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu

Blood (2023) 142 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2023-179555

Published: 2023

Journal Articles

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Melody Luo, PhD, Dolly A. Parasrampuria, PhD, Saad Z. Usmani, MD, Maria-Victoria Mateos, Hareth Nahi, MD PhD, Christoph Heuck, Ming Qi, MD PhD, Steven Sun, Pamela L. Clemens, PhD, Honghui Zhou, Yu-Nien (Tom) Sun, PhD, Steven Xu, PhD

Blood (2019) 134 (Supplement_1): 3151.

https://doi.org/10.1182/blood-2019-123405

Published: 2019

Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD

Blood (2018) 132 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2018-99-113161

Published: 2018

Journal Articles

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Xu Steven Xu, Philippe Moreau, Saad Z. Usmani, MD, Sagar Lonial, MD, Andrzej Jakubowiak, MD PhD, Albert Oriol, MD, Amrita Krishnan, MD, Joan Bladé, MD PhD, Melody Luo, PhD, Yu-Nien Sun, PhD, Liping Zhang, William Deraedt, Ming Qi, MD PhD, Jon Ukropec, PhD, Pamela L Clemens, PhD

Blood (2018) 132 (Supplement 1): 1970.

https://doi.org/10.1182/blood-2018-99-113171

Published: 2018

Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens

Blood (2016) 128 (22): 3340.

https://doi.org/10.1182/blood.V128.22.3340.3340

Published: 2016

Journal Articles

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Xu Steven Xu, Xiaoyu Yan, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Peter M. Voorhees, MD, Kevin Liu, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Juan Jose Perez Ruixo, Honghui Zhou, Pamela L Clemens

Blood (2015) 126 (23): 4254.

https://doi.org/10.1182/blood.V126.23.4254.4254

Published: 2015

Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu

Blood (2015) 126 (23): 4222.

https://doi.org/10.1182/blood.V126.23.4222.4222

Published: 2015

NARROW

Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only